Download PDF
Thromb Haemost 1967; 18(01/02): 133-149
DOI: 10.1055/s-0038-1655023
Originalarbeiten — Original Articles — Travaux Originaux
Schattauer GmbH

Studies with a Preparation of Urokinase

Anne H. C. Dubber M. B., Ph. D.
1   University Department of Medicine, Royal Infirmary, Glasgow (Scotland)
,
G. P McNicol M. D., Ph. D., M. R. C. P. (Ed. and Glasg.)
1   University Department of Medicine, Royal Infirmary, Glasgow (Scotland)
,
Patricia A. Wilson B. Sc.
1   University Department of Medicine, Royal Infirmary, Glasgow (Scotland)
,
A. S Douglas B. Sc., M. D., F. R. C. P. (Lond., Ed. and Glasg.), M. C. Path
1   University Department of Medicine, Royal Infirmary, Glasgow (Scotland)
› Author Affiliations
Further Information

Publication History

Publication Date:
26 June 2018 (online)

Also available at
    Permissions and Reprints

Summary

The evidence presented in this paper shows that though less coagulative than urokinase (Leo), urokinase (Abbott), both in vitro and in vivo, has coagulant activity. Further, evidence has been presented that urokinase may accelerate platelet aggregation. While it is likely that the intense fibrinolytic activity which may be produced by intravenous administration of urokinase would largely cancel out the coagulative activity in vivo, these properties in theory could predispose to thrombosis or perhaps more particularly to rethrombosis during therapy with urokinase and it would clearly be desirable, if possible, to obtain a preparation free from such coagulative properties.

 

  • References

  • 1 Fletcher A. P, AIkjaersig N, Sherry S, Genton E, Hirsch J, Bachman F. The development of urokinase as a thrombolytic agent. J. Lab. clin. Med. 65: 713 1965;
    PubMedSearch in Google Scholar
  • 2 Tocantins L. M, Lindquist J. N. Thromboplastic activity of the urine. Proc. Soc. exp. Biol. (N. Y) 65: 44 1947;
    CrossrefPubMedSearch in Google Scholar
  • 3 Caldwell M. J, von Kaulla K. N, von Kaulla E, Seegers W. H. Procoagulant material from human urine in prothrombin activation. Thrombos. Diathes. haemorrh. (Stuttg.) 09: 53 1963;
    PubMedSearch in Google Scholar
  • 4 McNicol G. P, Gale S. B, Douglas A. S. In-vitro and invivo studies of a preparation of urokinase. Brit. med. J. I: 909 1963;
    PubMedSearch in Google Scholar
  • 5 Ploug J, Kjeldgaard N. O. Urokinase, an activator of plasminogen from human urine. 1. Isolation and properties. Biochem. biophys. Acta. (Amst) 24: 278 1957;
    CrossrefPubMedSearch in Google Scholar
  • 6 Biggs R, Macfarlane R. G. Human blood coagulation and its disorders. 372 Blackwell, Oxford: 1962
    Search in Google Scholar
  • 7 Clement W. E, McNicol G. P. The preparation and use of 131I-tagged fibrinogen to demonstrate fibrinolysis. J. clin. Path. 12: 544 1959;
    CrossrefPubMedSearch in Google Scholar
  • 8 Kline D. L. The purification and crystallization of plasminogen (profibrinolysin). J. biol. Chem. 204: 949 1953;
    PubMedSearch in Google Scholar
  • 9 Douglas A. S. Anticoagulant therapy. 279 Blackwell, Oxford: 1962
    Search in Google Scholar
  • 10 Biggs R, Macfarlane R. G. Human blood coagulation and its disorders. 384 Blackwell, Oxford: 1962
    Search in Google Scholar
  • 11 Biggs R, Douglas A. S. The thromboplastin generation test. J. clin. Path. 06: 23 1963;
    PubMedSearch in Google Scholar
  • 12 Bell W. N, Alton H. G. A brain extract as a substitute for platelet suspensions in the thromboplastin generation test. Nature (Lond) 174: 880 1954;
    CrossrefPubMedSearch in Google Scholar
  • 13 Douglas A. S, Biggs R. The consumption of some components involved in physiological blood coagulation. Glasg. med. J. 34: 329 1953;
    PubMedSearch in Google Scholar
  • 14 Douglas A. S. Unpublished observations. 1965
    PubMedSearch in Google Scholar
  • 15 Douglas A. S. Unpublished observations. 1963
    PubMedSearch in Google Scholar
  • 16 Nussenzweig V, Seligmann M, Pelmont J, Grabar P. Les produits de degradation du fibrinogene humain par la plasmine. Ann. Inst. Pasteur. 100: 377 1961;
    PubMedSearch in Google Scholar
  • 17 Lowry O. H, Rosebrough N. J, Farr A. L, Randall R. L. Protein measurement with the Folin phenol reagent. J. biol. Chem. 193: 265 1951;
    PubMedSearch in Google Scholar
  • 18 Dacie J. V. Practical Haematology. 37 Churchill, London: 1956
    Search in Google Scholar
  • 19 Chandler A. B. In vitro thrombotic coagulation of the blood. Lab. Invest. 07: 110 1958;
    PubMedSearch in Google Scholar
  • 20 Cunningham G. M, McNicol G. P, Douglas A. S. Effect of anticoagulant drugs on platelet aggregation in the Chandler’s tube. Lancet I: 729 1965;
    PubMedSearch in Google Scholar
  • 21 AIkjaersig N, Fletcher A. P, Sherry S. The mechanism of clot dissolution by plasmin. J. clin. Invest. 38: 1086 1959;
    CrossrefPubMedSearch in Google Scholar
  • 22 McNicol G. P, Douglas A. S, Bayley C. Experience with streptokinase infusions. Lancet. II: 1297 1962;
    PubMedSearch in Google Scholar
  • 23 Nilsson I. M, Olow B. Fibrinolysis induced by streptokinase in man. Acta chir. scand. 123: 247 1962;
    PubMedSearch in Google Scholar
  • 24 Sherry S, Alkjaersig N. Studies on the fibrinolytic enzyme of human plasma. Thrombos. Diathes. haemorrh. (Stuttg) 01: 264 1957;
    PubMedSearch in Google Scholar
  • 25 Alkjaersig N, Fletcher A. P, Sherry S. E-aminocaproic acid: an inhibitor of plasminogen activation. J. biol. Chem. 234: 832 1959;
    PubMedSearch in Google Scholar
  • 26 Remmert L. F, Cohen P. P. Partial purification and properties of a proteolytic enzyme of human serum. J. biol. Chem. 181: 431 1949;
    PubMedSearch in Google Scholar
  • 27 McNicol G. P, Douglas A. S. The fibrinolytic enzyme system. In recent advances in clinical pathology. Dykes S. C. Ed. Series IV. 187 Churchill, London: 1964
    Search in Google Scholar
  • 28 Ratnoff O. D, Menzie G. A new method for the determination of fibrinogen in small samples of plasma. J. Lab. clin. Med. 37. : 316 1951;
    PubMedSearch in Google Scholar
  • 29 Fletcher A. P, Alkjaersig N, Sherry S. The maintenance of a sustained thrombolytic state in man. I. Induction and effects. J. clin. Invest. 38: 1096 1959;
    CrossrefPubMedSearch in Google Scholar
  • 30 Alkjaersig N, Fletcher A. P, Sherry S. The assay of urokinase preparations for contamination with thromboplastic moieties. J. Lab. clin. Med. 65: 732 1965;
    PubMedSearch in Google Scholar
  • 31 Iatridis S. G, Wilson E. G, Ferguson J. H, Rierson H. A. Blood clotting activities of thrombolytic agents with special reference to a Hageman-like effect. Thrombos. Diathes. haemorrh. (Stuttg) 05: 50 1960;
    PubMedSearch in Google Scholar
  • 32 Kowalski E, Kopec M, Wegrzynowicz Z. Influence of fibrinogen degradation products (FDP) on platelet aggregation, adhesiveness and viscous metamorphosis. Thrombos. Diathes. haemorrh. (Stuttg) 10: 406 1964;
    PubMedSearch in Google Scholar
  • 33 Hirsch J, Fletcher A. P, Sherry S. Effect of fibrin and fibrinogen proteolysis products on clot physical properties. Amer. J. Physiol. 209: 415 1965;
    PubMedSearch in Google Scholar
  • 34 Wilson P. Unpublished observations. 1966
    PubMedSearch in Google Scholar